Minervax
PrivateLast Round
Series C
Oct 11, 2023
Est. Valuation
$7.91M
Total Funding Raised
$173.64M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Minervax is a biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS) for maternal immunization and older adults.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Minervax Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Minervax Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 11, 2023 | ||||
| Debt | Dec 15, 2022 | ||||
| Series B | Dec 15, 2020 | ||||
| VC Round | Jan 21, 2019 | ||||
| Series A Extension | Feb 15, 2016 | ||||
Series A | Jan 9, 2014 |
Key People
Founding team and executive leadership
Minervax Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Heartcore Capital | Seed, Series A Extension |
| EQT Life Sciences | Series C |
| Trill Impact | Series C |
| Lund University Innovation System | Seed |
| LF Investment | Series C, Series A, Series B, Series A Extension, Debt |
| Trill Impact Ventures | Series C, Debt |
| Lauritzen Fonden | Series B, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors grew 38% MoM.
- Apr 17, 2026
Monthly visitors grew 212% MoM.
Minervax Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Minervax's valuation, stock price, and market status.